WO2023238952A9 - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
WO2023238952A9
WO2023238952A9 PCT/JP2023/021625 JP2023021625W WO2023238952A9 WO 2023238952 A9 WO2023238952 A9 WO 2023238952A9 JP 2023021625 W JP2023021625 W JP 2023021625W WO 2023238952 A9 WO2023238952 A9 WO 2023238952A9
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
buffering
agent
diphenylpyrazin
butoxy
Prior art date
Application number
PCT/JP2023/021625
Other languages
English (en)
French (fr)
Other versions
WO2023238952A1 (ja
Inventor
千晶 渕上
舞 森内
大貴 加藤
Original Assignee
日本新薬株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日本新薬株式会社 filed Critical 日本新薬株式会社
Publication of WO2023238952A1 publication Critical patent/WO2023238952A1/ja
Publication of WO2023238952A9 publication Critical patent/WO2023238952A9/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

本発明は、良好な保存安定性を有する、（２－（４－（（５，６－ジフェニルピラジン－２－イル）（イソプロピル）アミノ）ブトキシ）酢酸（化合物Ｂ）の薬学的に許容される塩を含有する医薬組成物を提供する。　本発明は、下記成分を含有する、医薬組成物である： （Ａ）（２－（４－（（５，６－ジフェニルピラジン－２－イル）（イソプロピル）アミノ）ブトキシ）酢酸の薬学的に許容される塩、 （Ｂ）塩基性領域に緩衝能を有する緩衝剤１及び中性領域に緩衝能を有する緩衝剤２、又は塩基性領域～中性領域に緩衝能を有する緩衝剤３、及び （Ｃ）ｐＨ調整剤。
PCT/JP2023/021625 2022-06-10 2023-06-09 医薬組成物 WO2023238952A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2022094537 2022-06-10
JP2022-094537 2022-06-10

Publications (2)

Publication Number Publication Date
WO2023238952A1 WO2023238952A1 (ja) 2023-12-14
WO2023238952A9 true WO2023238952A9 (ja) 2024-02-01

Family

ID=89118467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2023/021625 WO2023238952A1 (ja) 2022-06-10 2023-06-09 医薬組成物

Country Status (2)

Country Link
TW (1) TW202404594A (ja)
WO (1) WO2023238952A1 (ja)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190204A1 (ar) * 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
EP3982967A1 (en) * 2019-06-11 2022-04-20 Actelion Pharmaceuticals Ltd. Methods for treating pulmonary arterial hypertension
CN114206842A (zh) * 2019-08-19 2022-03-18 日本新药株式会社 盐
TW202239408A (zh) * 2021-01-29 2022-10-16 瑞士商艾克泰聯製藥有限公司 包含二苯基吡𠯤衍生物的醫藥組成物

Also Published As

Publication number Publication date
WO2023238952A1 (ja) 2023-12-14
TW202404594A (zh) 2024-02-01

Similar Documents

Publication Publication Date Title
JPH0774162B2 (ja) 水銀含有防腐剤を安定化した眼炎治療薬
US6008256A (en) Composition for local anesthesia
RS52214B (en) HDAC INHIBITOR PHARMACEUTICAL FORMULATIONS
JP2001158734A (ja) 眼科用組成物及びソフトコンタクトレンズに対する吸着抑制方法
EP1575585A1 (en) Pharmaceutical liquid composition containing pyridone derivative
KR20190128657A (ko) 의약 제제
EP0710108B1 (en) Liquid pharmaceutical composition for oral use containing 2-(4-isobutylphenyl)propionic acid
EA005676B1 (ru) Новая соль периндоприла и содержащие ее фармацевтические композиции
SK285374B6 (sk) Stabilný, nazálne, orálne alebo sublinguálne použiteľný farmaceutický prípravok
JP2009533462A (ja) ブリモニジンおよびチモロールの組成物
WO2005082416A3 (en) Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms
EP2578235A3 (en) Liquid formulation of G-CSF conjugate
WO2023238952A9 (ja) 医薬組成物
JP2023062143A (ja) 水性組成物
EP1532981B1 (en) Stable eye drops containing latanoprost as the active ingredient
WO2002000166A3 (en) New compounds useful as antibacterial agents
US9238037B2 (en) Enema composition for treatment of ulcerative colitis having long term stability
IE36337L (en) Pharmaceutical compositions
CN104812370B (zh) 包含2-氨基-3-(4-溴苯甲酰基)苯基乙酸的含水液体组合物
US20230390295A1 (en) Pemetrexed formulations
JP2005263792A (ja) 澄明なラタノプロスト点眼液
JP5922609B2 (ja) ２−アミノ−３−（４−ブロモベンゾイル）フェニル酢酸含有水性組成物
WO2022080397A1 (ja) 安定な医薬組成物
JP2009040727A (ja) ラタノプロストを有効成分とする安定な点眼液剤
WO2017170626A1 (ja) 水性液剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23819932

Country of ref document: EP

Kind code of ref document: A1